# Rigel Pharmaceuticals (RIGL) — News

RIGL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rigl/news

## Recent headlines

- [Info Edge Board OKs ~INR 1B investment in unit 5IHL](https://www.ainvest.com/news/info-edge-board-oks-inr-1b-investment-unit-5ihl-2610) — AInvest Wire, Oct 13, 2026
  Info Edge (India) Limited has approved an investment of approximately INR 1 billion in its subsidiary, 5IHL, as part of its strategic capital allocation plans. The investment, approved by the company’s board of directors, is intended to support the subsidiary’s operational requirements and to…
- [Knight Therapeutics - Expects Tavalisse launch in Colombia in first half of 2027](https://www.ainvest.com/news/knight-therapeutics-expects-tavalisse-launch-colombia-2027-2609) — AInvest Wire, Sep 1, 2026
  Knight Therapeutics Inc. (TSX: GUD) has indicated that it expects to launch TAVALISSE® (fostamatinib disodium hexahydrate) in Colombia during the first half of 2027, according to regulatory and commercial timelines previously disclosed by the company. This follows the successful regulatory approval…
- [Rigel Pharmaceuticals, Inc.: H.C. Wainwright raises target price to $85 from $57](https://www.ainvest.com/news/rigel-pharmaceuticals-wainwright-raises-target-price-85-57-2608) — AInvest Wire, Aug 14, 2026
  On August 5, 2026, H.C. Wainwright revised its price target for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), raising it from $57 to $85, while maintaining its "Buy" rating . This update follows Rigel’s strong quarterly performance, where the biotechnology firm reported earnings of $0.88 per…
- [Rigel Pharma 2Q total revenue $78.7M, est. $69.1M](https://www.ainvest.com/news/rigel-pharma-2q-total-revenue-78-7m-est-69-1m-2608) — AInvest Wire, Aug 4, 2026
- [Rigel Pharma 2Q R&D expenses $14.0M, est. $12.7M](https://www.ainvest.com/news/rigel-pharma-2q-expenses-14-0m-est-12-7m-2608) — AInvest Wire, Aug 4, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).